67 related articles for article (PubMed ID: 21721105)
1. Transient partial response to sorafenib treatment in an adolescent patient with MEN2B syndrome and end-stage medullary thyroid carcinoma.
Aller S; Popescu A; Rao S; Morgan E; Gosiengfiao Y
Pediatr Blood Cancer; 2012 Jan; 58(1):98-100. PubMed ID: 21721105
[TBL] [Abstract][Full Text] [Related]
2. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
Hong D; Ye L; Gagel R; Chintala L; El Naggar AK; Wright J; Kurzrock R
Mol Cancer Ther; 2008 May; 7(5):1001-6. PubMed ID: 18445656
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib induces partial response in metastatic medullary thyroid carcinoma.
Spector E; Franklin MJ; Truskinovsky AM; Dudek AZ
Acta Oncol; 2010; 49(1):104-6. PubMed ID: 19711206
[No Abstract] [Full Text] [Related]
4. Rapid response to sorafenib in metastatic medullary thyroid carcinoma.
Frank-Raue K; Ganten M; Kreissl MC; Raue F
Exp Clin Endocrinol Diabetes; 2011 Mar; 119(3):151-5. PubMed ID: 20827665
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib in metastatic thyroid cancer.
Capdevila J; Iglesias L; Halperin I; Segura A; Martínez-Trufero J; Vaz MÁ; Corral J; Obiols G; Grande E; Grau JJ; Tabernero J
Endocr Relat Cancer; 2012 Apr; 19(2):209-16. PubMed ID: 22285864
[TBL] [Abstract][Full Text] [Related]
6. Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes.
Quayle FJ; Moley JF
J Surg Oncol; 2005 Mar; 89(3):122-9. PubMed ID: 15719378
[TBL] [Abstract][Full Text] [Related]
7. Novel treatment of medullary thyroid cancer.
Sugawara M; Geffner DL; Martinez D; Hershman JM
Curr Opin Endocrinol Diabetes Obes; 2009 Oct; 16(5):367-72. PubMed ID: 19633548
[TBL] [Abstract][Full Text] [Related]
8. Update on medullary thyroid cancer.
Hu MI; Ying AK; Jimenez C
Endocrinol Metab Clin North Am; 2014 Jun; 43(2):423-42. PubMed ID: 24891170
[TBL] [Abstract][Full Text] [Related]
9. Metastatic medullary carcinoma of the vulva in a patient with MEN IIb syndrome.
Thomakos N; Rodolakis A; Akrivos N; Skampardonis N; Sotiropoulou M; Biliatis I; Alevizaki M; Antsaklis A
In Vivo; 2010; 24(5):791-4. PubMed ID: 20952752
[TBL] [Abstract][Full Text] [Related]
10. Ectopic Cushing syndrome secondary to metastatic medullary thyroid cancer in a child with multiple endocrine neoplasia syndrome type 2B: clues to early diagnosis of the paraneoplastic syndromes.
Singer K; Heiniger N; Thomas I; Worden FP; Menon RK; Chen M
J Pediatr Endocrinol Metab; 2014 Sep; 27(9-10):993-6. PubMed ID: 24859505
[TBL] [Abstract][Full Text] [Related]
11. The successful use of sorafenib to treat pediatric papillary thyroid carcinoma.
Waguespack SG; Sherman SI; Williams MD; Clayman GL; Herzog CE
Thyroid; 2009 Apr; 19(4):407-12. PubMed ID: 19355831
[TBL] [Abstract][Full Text] [Related]
12. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.
Naito S; Tsukamoto T; Murai M; Fukino K; Akaza H
BJU Int; 2011 Dec; 108(11):1813-9. PubMed ID: 21481133
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
Schlumberger MJ; Elisei R; Bastholt L; Wirth LJ; Martins RG; Locati LD; Jarzab B; Pacini F; Daumerie C; Droz JP; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Sherman SI
J Clin Oncol; 2009 Aug; 27(23):3794-801. PubMed ID: 19564535
[TBL] [Abstract][Full Text] [Related]
14. Reports of clinical benefit of plitidepsin (Aplidine), a new marine-derived anticancer agent, in patients with advanced medullary thyroid carcinoma.
Le Tourneau C; Faivre S; Ciruelos E; Domínguez MJ; López-Martín JA; Izquierdo MA; Jimeno J; Raymond E
Am J Clin Oncol; 2010 Apr; 33(2):132-6. PubMed ID: 19687728
[TBL] [Abstract][Full Text] [Related]
15. Medullary thyroid carcinoma in a 2-month-old male with multiple endocrine neoplasia 2B and symptoms of pseudo-Hirschsprung disease: a case report.
Unruh A; Fitze G; Jänig U; Bielack S; Lochbühler H; Coerdt W
J Pediatr Surg; 2007 Sep; 42(9):1623-6. PubMed ID: 17848262
[TBL] [Abstract][Full Text] [Related]
16. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy.
Fagin JA
J Endocrinol; 2004 Nov; 183(2):249-56. PubMed ID: 15531713
[TBL] [Abstract][Full Text] [Related]
17. Medullary carcinoma of the thyroid gland and the MEN 2 syndromes.
Skinner MA; Wells SA
Semin Pediatr Surg; 1997 Aug; 6(3):134-40. PubMed ID: 9263335
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
Elser C; Siu LL; Winquist E; Agulnik M; Pond GR; Chin SF; Francis P; Cheiken R; Elting J; McNabola A; Wilkie D; Petrenciuc O; Chen EX
J Clin Oncol; 2007 Aug; 25(24):3766-73. PubMed ID: 17704426
[TBL] [Abstract][Full Text] [Related]
19. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers.
Sherman SI
J Clin Endocrinol Metab; 2009 May; 94(5):1493-9. PubMed ID: 19258410
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma.
Diamantis ML; Chon SY
J Drugs Dermatol; 2010 Feb; 9(2):169-71. PubMed ID: 20214183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
